Clinical Trials Logo

Clpd-Nk clinical trials

View clinical trials related to Clpd-Nk.

Filter by:
  • None
  • Page 1

NCT ID: NCT04453345 Recruiting - T-LGL Leukemia Clinical Trials

TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL

Start date: May 20, 2013
Phase: Phase 2/Phase 3
Study type: Interventional

Large granular lymphocytic leukemia (LGLL) is a lymphoproliferative disease, with LGL infiltration in peripheral blood and bone marrow, hepatosplenomegaly, and cytopenia. Both T-LGLL and CLPD-NK are indolent disease and share similar biology and clinical course, and treated under the same strategy. So the investigators put them together as LGLL. The investigators used TPM regimen (thalidomide + prednison + methotrexate ) to treat LGLL since 2013, and 18/20 patients (90%) obtained clinical response, including 80% complete response. Adverse events (AE) of grade 3 and above are rare and safe. Therefore, the investigators designed this multicenter clinical trial to validate the efficacy of the TPM regimen in symptomatic T-LGLL and CLPD-NK.